Free Trial

Novartis AG (NYSE:NVS) Shares Bought by Fisher Asset Management LLC

Novartis logo with Medical background

Fisher Asset Management LLC grew its holdings in Novartis AG (NYSE:NVS - Free Report) by 1.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,430,609 shares of the company's stock after acquiring an additional 22,397 shares during the quarter. Fisher Asset Management LLC owned 0.07% of Novartis worth $144,449,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of NVS. Murphy Middleton Hinkle & Parker Inc. raised its stake in Novartis by 4.9% in the 4th quarter. Murphy Middleton Hinkle & Parker Inc. now owns 2,072 shares of the company's stock worth $209,000 after acquiring an additional 97 shares during the last quarter. Pinnacle Bancorp Inc. raised its stake in shares of Novartis by 2.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 3,641 shares of the company's stock worth $368,000 after purchasing an additional 98 shares during the last quarter. Optimum Investment Advisors lifted its holdings in shares of Novartis by 23.3% during the fourth quarter. Optimum Investment Advisors now owns 530 shares of the company's stock worth $54,000 after purchasing an additional 100 shares during the period. Chesley Taft & Associates LLC boosted its position in Novartis by 0.3% in the fourth quarter. Chesley Taft & Associates LLC now owns 33,062 shares of the company's stock valued at $3,338,000 after buying an additional 100 shares during the last quarter. Finally, Means Investment CO. Inc. increased its holdings in Novartis by 1.3% in the 4th quarter. Means Investment CO. Inc. now owns 8,074 shares of the company's stock worth $815,000 after buying an additional 103 shares during the period. Hedge funds and other institutional investors own 13.12% of the company's stock.

Novartis Price Performance

Shares of NVS stock traded down $0.30 on Friday, reaching $105.72. 2,565,119 shares of the company were exchanged, compared to its average volume of 1,162,880. Novartis AG has a 1 year low of $92.19 and a 1 year high of $108.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.71 and a current ratio of 0.90. The business has a 50-day moving average price of $99.84 and a 200 day moving average price of $100.63. The company has a market cap of $216.09 billion, a price-to-earnings ratio of 14.27, a P/E/G ratio of 1.62 and a beta of 0.58.


Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Tuesday, April 23rd. The company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.07. Novartis had a return on equity of 32.15% and a net margin of 31.33%. The firm had revenue of $11.83 billion for the quarter, compared to analyst estimates of $11.50 billion. Equities research analysts forecast that Novartis AG will post 7.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on NVS shares. The Goldman Sachs Group assumed coverage on shares of Novartis in a report on Thursday, May 30th. They issued a "buy" rating and a $120.00 price target on the stock. BMO Capital Markets upped their target price on Novartis from $114.00 to $116.00 and gave the stock a "market perform" rating in a research note on Wednesday, April 24th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $116.67.

Read Our Latest Report on NVS

About Novartis

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Read More

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Novartis right now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines